Calico Life Sciences LLC

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Available

Expanded Access to ABBV-CLS-484

Jul 2, 2026

Recruiting

A Phase 1b/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following Fosigotifator Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease

Earlier

May 21, 2024TrialStudy of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

Mar 14, 2024TrialA Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

Dec 19, 2023TrialA Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262

Mar 24, 2023TrialA Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

Mar 9, 2021TrialStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)